LataMed AI Corp. (OTC: LMED), a healthcare technology company focused on Latin America, announced that its mobile healthcare application has entered the final development stage. The company is completing testing, optimization, and deployment preparations ahead of a planned release through the Apple App Store and Google Play. Management expects to submit the app for distribution in the coming weeks, subject to platform review and technical requirements.
This move represents a significant transition from application development toward public availability, providing users with a primary mobile access point to LataMed AI’s digital healthcare ecosystem. The app aims to offer a convenient interface for accessing supported healthcare services and digital tools, with future functionality potentially including patient-facing tools, healthcare-provider interaction, digital communications, and healthcare-service coordination.
Mobile accessibility is particularly crucial in Latin America, where smartphones are the primary means of accessing digital services for many individuals. By launching on both major app stores, LataMed AI intends to offer a direct and accessible way for users to engage with its developing healthcare ecosystem, while also establishing infrastructure for future expansion.
The application is expected to support the company’s long-term strategy of connecting patients, healthcare professionals, pharmacies, insurers, payment providers, and wellness organizations within an integrated digital healthcare environment. LataMed AI continues to develop its AI-supported technologies, including CardioAI, PulmoAI, and NeuroAI, as part of its broader strategy. The mobile infrastructure aims to provide an additional pathway for users and professionals to interact with these components, subject to development, testing, and regulatory requirements.
“Our mobile application is now moving from development toward deployment, and we believe we are approaching an important milestone for LataMed AI,” said Dr. Kevin Rodan Levy, CEO. “Our team is completing the final stages of testing and preparation, and we currently expect the application to become available through the Apple App Store and Google Play in the coming weeks, subject to the applicable platform review processes.”
Dr. Levy emphasized the importance of mobile availability: “Mobile availability is important because it provides a direct connection between users and the digital healthcare ecosystem we are building. Our objective is to create a platform that is practical, accessible, and capable of expanding as we continue introducing additional healthcare services and artificial intelligence-supported tools.”
The anticipated release represents another step in moving LataMed AI’s technology from development into user-facing digital healthcare infrastructure. Following the initial launch, the company plans to evaluate additional functionality and integrations for future versions. Updates will be provided as milestones are completed.
For more information, visit https://latamed.ai or review the company’s SEC filings at www.sec.gov.
